Advanced search
Publication Cover
Journal of Hepatocellular Carcinoma Volume 10, 2023 - Issue
Submit an article Journal homepage
305
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma

Leijuan Gan1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9747-6053View further author information
ORCID Icon,
Mengran Lang1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of China;4 Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, Hebei, 065001, People’s Republic of ChinaView further author information
,
Xindi Tian1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
,
Shaohua Ren1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-4400-9045View further author information
ORCID Icon,
Guangtao Li1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
,
Yayue Liu1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
,
Ruyu Han1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-3565-1116View further author information
ORCID Icon,
Kangwei Zhu1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
,
Huikai Li1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
,
Qiang Wu1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
,
Yunlong Cui1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
,
Wei Zhang1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
,
Feng Fang1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
,
Qiang Li1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaView further author information
&
Tianqiang Song1 Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People’s Republic of China;2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China;3 Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5979-5213View further author information
ORCID Icon show all
Pages 673-686 | Received 25 Jan 2023, Accepted 30 Mar 2023, Published online: 22 Apr 2023

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jia-Yi Wu, Jun-Yi Wu, De-Yi Liu, Han Li, Shao-Wu Zhuang, Bin Li, Jian-Yin Zhou, Jing-Yao Huang, Zhi-Bo Zhang, Shu-Qun Li, Mao-Lin Yan & Yao-Dong Wang. (2023) Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?. Journal of Hepatocellular Carcinoma 10, pages 2161-2171.
Read now
Bingran Yu, Ning Zhang, Yun Feng, Yongfa Zhang, Ti Zhang & Lu Wang. (2023) Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 10, pages 1709-1721.
Read now

Articles from other publishers (2)

Ya-nan MaXuemei JiangHui LiuPeipei SongWei Tang. (2023) Conversion therapy for initially unresectable hepatocellular carcinoma: Current status and prospects. BioScience Trends 17:6, pages 415-426.
Crossref
Xuelei He, Kai Li, Ran Wei, Mengxuan Zuo, Wang Yao, Zechen Zheng, Xiaowei He, Yan Fu, Chengzhi Li, Chao An & Wendao Liu. (2023) A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy. La radiologia medica 128:12, pages 1508-1520.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.